Mantle Cell Lymphoma

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses safety and efficacy findings for acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed/refractory mantle cell lymphoma (MCL) during the 2018 ASH Annual Meeting.

Robert Dean, MD, a staff physician at Cleveland Clinic, discusses ongoing research on biomarkers in mantle cell lymphoma (MCL).

Jonathon B. Cohen, MD, discusses the evolving landscape of mantle cell lymphoma.

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the use of CAR T-cell therapy in patients with mantle cell lymphoma.

Simon Rule, MD, PhD, discusses the observational and active therapeutic approaches for patients with mantle cell lymphoma.

Robert Dean, MD, discusses the promise for new therapies in mantle cell lymphoma.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses new agents in the field of mantle cell lymphoma (MCL).

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical Center, United Kingdom, discusses the treatment of patients with p53-mutated mantle cell lymphoma.

Bijal D. Shah, MD, associate member, Department of Malignant Hematology, Moffitt Cancer Center, discusses the challenges in treating patients with high-risk mantle cell lymphoma (MCL).

Robert Dean, MD, staff physician, Cleveland Clinic, discusses the evolution of treatment approaches in mantle cell lymphoma (MCL).

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, addresses questions on the watch-and-wait approach in mantle cell lymphoma.

Lawrence D. Kaplan, MD, discusses recent updates and next steps in the expanding paradigm of Hodgkin lymphoma, mantle cell lymphoma, and follicular lymphoma.

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the potential of Bruton tyrosine kinase (BTK) inhibitors in the frontline treatment of patients with mantle cell lymphoma (MCL).

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses the challenges of developing clinical trials for CAR T cells in mantle cell lymphoma.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with relapsed/refractory mantle cell lymphoma.

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses combination therapy for patients with mantle cell lymphoma.

Chaitra S. Ujjani, MD, discusses the latest progress in both Hodgkin lymphoma and mantle cell lymphoma.

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses the “watching and waiting” approach for a subset of patients with mantle cell lymphoma.

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in mantle cell lymphoma (MCL).

B-cell malignancies are a heterogeneous subset of non-Hodgkin lymphomas in which treatment has remained essentially unchanged for the past 3 decades.

Nathan H. Fowler, MD, discusses the use of BTK inhibitors in B-cell malignancies.

Among the many new developments in B-cell lymphoma in recent years, the inhibition of Bruton tyrosine kinase represents a particularly notable achievement.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses how to manage adverse events related to BTK inhibitors in the treatment of mantle cell lymphoma.

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses the treatment of patients with p53-mutated mantle cell lymphoma.

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the treatment of patients with mantle cell lymphoma.